Ignite Creation Date:
2025-12-24 @ 1:57 PM
Ignite Modification Date:
2026-04-15 @ 10:09 PM
Study NCT ID:
NCT05911295
Status:
RECRUITING
Last Update Posted:
2025-12-15
First Post:
2023-06-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SGNDV-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None